A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2016
At a glance
- Drugs MORAb 022 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Morphotek
- 07 Dec 2015 Results published in a Morphotek media release.
- 12 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2014 Planned End Date changed from 1 May 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.